FCH
GNMK

Freestone Capital Holdings’s GenMark Diagnostics, Inc GNMK Stock Holding History

Freestone Capital Holdings’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$14.6K – 1272
2020
Q4 		$14.6K Hold
1,000
– – ﹤0.01% 783
2020
Q3 		$14.2K Buy
+1,000
New +$15.3K ﹤0.01% 697

Other funds holding GNMK

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Freestone Capital Holdings's GNMK Position: Q1 2021 in Review

Freestone Capital Holdings sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 1,000 shares — an estimated $14.6K sold.

Freestone Capital Holdings first reported a position in GNMK in Q3 2020 and held it in 2 quarters. The position peaked at $14.6K in Q4 2020. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

  • Freestone Capital Holdings reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 1,000 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $14.6K.
  • Freestone Capital Holdings first reported a position in GenMark Diagnostics, Inc in Q3 2020 and held it in 2 quarters.
  • Freestone Capital Holdings's GenMark Diagnostics, Inc position peaked at $14.6K in Q4 2020.
  • 164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.